Response to bosentan in children with pulmonary hypertension.
about
Drug treatment of pulmonary hypertension in childrenPharmacotherapy for pulmonary hypertensionPulmonary Hypertension in Children.Pediatric pulmonary arterial hypertension.Pulmonary hypertension in children with Evans syndrome.Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophyChallenges in the development of chronic pulmonary hypertension models in large animalsPrenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheepA bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settingsHemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertensionShort- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.Non-congenital heart disease associated pediatric pulmonary arterial hypertensionPulmonary hypertension in bronchopulmonary dysplasiaAdvances in pediatric pulmonary arterial hypertension.A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.Management and therapeutic options in pediatric pulmonary hypertension.Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Stability of an Extemporaneously Compounded Oral Suspension of Bosentan.The management of pulmonary hypertension in children.Treatment of pediatric pulmonary hypertensionCurrent challenges in pediatric pulmonary hypertension.Six-Minute Walk Test as a Predictor for Outcome in Children with Dilated Cardiomyopathy and Chronic Stable Heart Failure.Advances in therapies for pediatric pulmonary arterial hypertension.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Management of pulmonary hypertension and Down syndrome.The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia.Paediatric pulmonary hypertension and sildenafil: current practice and controversies.Current and advancing treatments for pulmonary arterial hypertension in childhood.Pharmacodynamic considerations in the treatment of pulmonary hypertension in infants: challenges and future perspectives.Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.Diagnosis and treatment of pulmonary hypertension in infancy.Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.Bilateral lung transplantation for pediatric idiopathic pulmonary arterial hypertension: a multi-center experience.Intermediate- and long-term follow-up of device closure of patent arterial duct with severe pulmonary hypertension: factors predicting outcome.Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.Antenatal hypoxia and pulmonary vascular function and remodeling.
P2860
Q26996078-FA98D4D9-C729-481E-A562-CA4D91793678Q27022763-F3B7AF2A-6B98-4448-ABD5-A49983A12C6BQ30248871-3B82BBC2-7451-4E02-8B08-A166359F6801Q33163446-F40CC405-A4CE-4BA3-B787-43D027A497D8Q33379056-2960B110-1E8F-49C6-B5C4-BBAC0F0FEDE9Q33588179-79CD3DEB-7C99-44DA-A3E2-B7DAD52A2A6BQ33730357-9E3A5491-771F-4B34-9BE6-A2BAFEE152DCQ33738598-05A080E3-4131-458A-97F4-058AA3D56730Q33806234-4A65933B-CBEC-4A72-A0C1-740F84646FD4Q33903698-416116C4-3144-496C-89B7-886EB74498ADQ34254924-F6285076-0422-46DD-A70C-BB8FB94B6578Q35069848-98BB54B8-2935-4702-913D-F00198A09F5CQ35076114-F5AC04DA-048C-4E5F-9167-CECF0AD01090Q35165691-FFF7337C-DC40-4A8F-B648-15F88EF94858Q35731631-9F5982A8-9AD7-4BBE-A8D0-F0AAC19F9196Q35869437-554195D3-8776-4633-994C-EDC2A0C7ACA9Q36481525-24C6CC31-C49C-44A7-B4E2-3A4B8BBE4026Q36484917-CA9F2D68-CBEA-4106-9CB1-A9B20D5E840BQ36570843-E155B007-DC66-4F86-BAC9-FD5D066EF44CQ36763080-84E3B7EF-2F38-4E57-8508-BC71911572E0Q36977243-F8ACEDFB-3BAE-43D6-B9EB-26C072BE1580Q37125318-3700618A-0C94-48A5-BFD1-834F64218544Q37230469-98AD5442-9C51-41E5-8752-B5A4D590DDFDQ37540613-DE1C7AB8-A996-4AD2-AF54-1E3C2524699EQ37707309-206F456D-644A-47DE-8486-B692190FE122Q37755020-EB724016-57FA-47FF-B8C5-0FCCFA7FBA89Q37879213-8EB6E645-E5E8-42E5-B34C-63B53C403252Q37968663-ED181B77-1F21-473A-9E04-5E4C7B5788C3Q38102665-3511B310-F04C-494E-9182-82AAD19A0E65Q38114863-C20CCA72-8437-435A-9F0D-83E73A45DDCEQ38232339-4ECD00F9-66C6-40A0-9103-6C38163C6C40Q38630552-633CF4F3-6A36-4F5C-821E-B94A3E044B35Q39992496-78F99C31-809A-4C33-950D-C1DCE339D786Q42012709-24CB5E56-A632-49D9-B1C9-D6C39AAD5D3DQ42508912-B0746D4B-6D17-45D3-92E1-A7F513A8B797Q43527880-182F20C5-F1EC-4737-96A0-17F0862B907DQ44426914-3E5B042E-D01F-411A-A760-F13E3449FB1CQ51349756-C0E9F905-71A5-4F63-9EFD-21CEC4219D55Q55001904-DBBC617C-9642-452C-98A4-BBCA27337A42Q55110701-701756BD-8C91-4FAB-BB54-C2D256F09FEB
P2860
Response to bosentan in children with pulmonary hypertension.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Response to bosentan in children with pulmonary hypertension.
@ast
Response to bosentan in children with pulmonary hypertension.
@en
type
label
Response to bosentan in children with pulmonary hypertension.
@ast
Response to bosentan in children with pulmonary hypertension.
@en
prefLabel
Response to bosentan in children with pulmonary hypertension.
@ast
Response to bosentan in children with pulmonary hypertension.
@en
P2093
P2860
P356
P1433
P1476
Response to bosentan in children with pulmonary hypertension.
@en
P2093
P2860
P304
P356
10.1136/HRT.2005.072314
P407
P577
2005-10-10T00:00:00Z